Combination immunotherapy [15,16], pre-existing autoimmunity [15,16] and certain types of cancer such as those associated with spontaneously occurring paraneoplastic neurological syndromes (i.e., lung or neuroendocrine malignancies) [15] seem to be implicated in development of PD-1 inhibitor-associated neuropathy. The gene discussed is PDCD1; the disease is cancer.